Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysis.

The article analyzes ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2-negative breast cancer patients in Israel. Topics include reports that the Recurrence Score (RS) assay is widely used in ER + HER2-negative breast cancer (BC); and examines goals of retrospective analysis to compare the Israeli Jewish vs Arab/Druze populations with respect to RS distribution, chemotherapy use and clinical outcomes in patients who were RS-tested through Clalit Health Services (CHS).